Beaumont Financial Advisors LLC Has $7.10 Million Stock Holdings in Abbott Laboratories $ABT

Posted by Stanley Muller on Jul 16th, 2026

Beaumont Financial Advisors LLC increased its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 193.8% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 69,183 shares of the healthcare product maker’s stock after acquiring an additional 45,634 shares during the period. Beaumont Financial Advisors LLC’s holdings in Abbott Laboratories were worth $7,103,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Cornerstone Financial Management LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at $25,000. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories during the 4th quarter valued at about $25,000. Purpose Unlimited Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories during the fourth quarter worth about $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $26,000. 75.18% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ABT has been the topic of several research analyst reports. Wells Fargo & Company decreased their target price on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Argus decreased their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Mizuho dropped their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Piper Sandler reiterated an “overweight” rating and set a $115.00 target price on shares of Abbott Laboratories in a research report on Monday, June 22nd. Finally, Oppenheimer decreased their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $117.61.

View Our Latest Stock Analysis on ABT

Abbott Laboratories Trading Up 0.3%

NYSE ABT opened at $89.27 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock’s 50-day moving average is $89.33 and its 200-day moving average is $102.36. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The firm has a market cap of $155.49 billion, a P/E ratio of 25.01, a P/E/G ratio of 1.53 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the business posted $1.09 earnings per share. Sell-side analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insiders Place Their Bets

In other news, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.